SLS Stock Soars More Than 200% After Phase 3 Cancer Vaccine Success: What’s Next for SELLAS Life Sciences?
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
SELLAS Life Sciences (SLS) shares surged more than 200% after the company reported positive Phase 3 results for its cancer vaccine in acute myeloid leukemia, showing a 41% reduction in the risk of death among treated patients. The rally ranks among the market's largest single-day gainers and marks a major clinical milestone for the small-cap biotech. The data give SELLAS a potential path toward regulatory submission for the vaccine in AML, a hard-to-treat blood cancer. Investors will watch for the full trial dataset, any FDA engagement on a filing timeline, and whether the company can secure the financing needed to support commercialization.
Muhabbit's AI wrote this summary in its own words from Coinpedia's report. It can get details wrong, so check the source.
Named in this story
SELLAS Life Sciences, SLS